Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
Wegovy pill available in Australia from today by private prescription
November 20, 2026 - - Latest News -
It happened last time, so it makes sense to start next week assuming it as the base case
November 20, 2026 - - Latest News -
Applying the principles of the Reserve Bank review to HTA advisory committees
November 20, 2026 - - Latest News -
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News

